Sunitinib Malate Capsule
Product Images NDC 43598-045

This is a prescription drug called Sunitinib Malate that comes in capsules of 12.5mg. Each capsule contains sunitinib malate 16.7mg equivalent to 125mg sunitinib. It is advised to dispense the enclosed medication guide to each patient. The usual dosage and storage instructions are mentioned in the accompanying prescribing information. The drug is distributed by Dr. Reddy's Laboratories Inc. located in Princeton, NJ, and it is made in India.*

This is a prescription drug with the National Drug Code (NDC) of 43598-046-63. The medicine is available in capsule form and each capsule contains 33.4 mg of sunitinib malate. The drug is used to treat cancer and there is additional prescribing information available. It is recommended to store the capsules between 20°C to 25°C but excursions are permitted to 15°C to 30°C. The medication should be dispensed in tight containers. The package contains 28 capsules and includes a medication guide for patients. This drug is made in India by Dr. Reddy's Laboratories Inc., and the code number is xx/x000/ /3000.*

Sunitinib Malate Capsules are a medication prescribed to patients with RxOnly label and NDC 43598-047-63 number. The capsules are sold in a container labeled with 28 capsules weighing 37.5 mg each. The medication guide is given to every patient to ensure safe use, and the usual dosage is provided in the accompanying prescription information. The capsules should be stored between 20°C to 25°C, with excursions permitted to 15°C to 30°C (59°F to 86°F). The product should be dispensed in tightly closed containers, and the code indicates that it's from AP/DRUGS/33/2007 series. The distributor is Dr. Reddy’s Laboratories Inc. based in Princeton, NJ 08540, and the capsules are made in India.*

This is a prescription medication called Sunitinib Malate Capsules, with an NDC number 43598-048-63. Each capsule contains 66.8 mg of sunitinib malate equivalent to 50 mg sunitinib. It is important to dispense the enclosed medication guide to each patient. The recommended dosage and other relevant information are in the accompanying prescribing instructions. It should be stored at a temperature of 20°C to 25°C (68°F to 77°F) with excursions allowed to 15°C to 30°C (59°Fto 86°F) and dispensed in tight containers. The manufacturer is Dr. Reddy’s Laboratories Inc. and the drug’s expiration date is 103/2022.*

This is a medical study comparing the effectiveness of Sunitinib malate and IFN-o treatments for an unknown condition. The study involved 375 participants for each treatment, and the median survival time was 47.3 weeks for the former and 22.0 weeks for the latter. The Hazard Ratio was 0.42, indicating a significant improvement in survival time for patients treated with Sunitinib malate. The results are supported by a probability table and statistical test (p < 0.000001).*

This is a statistical analysis comparing the disease-free survival rate between patients who received Sunitinib Malate and placebo for a median period of 6.8 years and 5.6 years, respectively. The Hazard Ratio for Sunitinib Malate is given as 0.76 with a confidence interval of 95%. Additionally, a p-value of 0.03 suggests that there is a statistically significant difference between the two groups. The table indicates the number of subjects at risk over time.*

This appears to be a table describing a clinical trial involving two groups of participants, one receiving sunitinib malate and the other receiving a placebo. The table includes information on the number of subjects, median survival times, and hazard ratio. There is also a graph displaying the number of subjects at risk over time for each group. However, without proper formatting and more context it is difficult to fully understand the information presented here.*